Q3 EPS Forecast for Ionis Pharmaceuticals Reduced by Analyst

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share estimate for Ionis Pharmaceuticals from ($1.17) to ($1.19), while the consensus estimate for FY2025 is now ($2.77) per share.
• Despite a challenging outlook, Ionis Pharmaceuticals recorded a significant revenue increase of 100.9% year-over-year, reaching $452 million in the last quarter.
• Barclays and several other brokerages have upgraded their ratings on Ionis Pharmaceuticals, with Barclays raising its price target from $51.00 to $57.00.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.19) per share for the quarter, down from their previous estimate of ($1.17). The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals' Q4 2025 earnings at ($1.41) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($3.92) EPS, FY2027 earnings at ($1.79) EPS and FY2028 earnings at ($1.72) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to the consensus estimate of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%. The company's quarterly revenue was up 100.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.45) earnings per share.

IONS has been the subject of several other reports. Guggenheim lowered their price objective on Ionis Pharmaceuticals from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. JPMorgan Chase & Co. increased their price objective on Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a research note on Thursday, June 12th. Morgan Stanley raised Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $55.00 to $62.00 in a research note on Thursday, July 31st. HC Wainwright reaffirmed a "buy" rating and set a $65.00 price target (up from $50.00) on shares of Ionis Pharmaceuticals in a research report on Thursday, July 31st. Finally, Raymond James Financial increased their price target on Ionis Pharmaceuticals from $60.00 to $64.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $59.38.

Ionis Pharmaceuticals Stock Up 1.4%

Shares of Ionis Pharmaceuticals stock traded up $0.59 on Friday, hitting $41.64. The company had a trading volume of 1,739,246 shares, compared to its average volume of 2,003,101. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of -22.63 and a beta of 0.25. Ionis Pharmaceuticals has a 1 year low of $23.95 and a 1 year high of $50.43. The stock has a 50 day moving average of $39.95 and a 200-day moving average of $34.47. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eugene Schneider sold 9,549 shares of the firm's stock in a transaction on Monday, August 4th. The stock was sold at an average price of $42.80, for a total value of $408,697.20. Following the completion of the sale, the executive vice president directly owned 51,507 shares of the company's stock, valued at $2,204,499.60. This trade represents a 15.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Richard S. Geary sold 10,000 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $42.86, for a total value of $428,600.00. Following the completion of the sale, the executive vice president directly owned 89,492 shares of the company's stock, valued at $3,835,627.12. This represents a 10.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,141 shares of company stock valued at $1,204,806. Corporate insiders own 2.60% of the company's stock.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. CWM LLC grew its position in shares of Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company's stock valued at $73,000 after purchasing an additional 384 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Ionis Pharmaceuticals by 3.9% in the second quarter. PNC Financial Services Group Inc. now owns 11,411 shares of the company's stock valued at $451,000 after purchasing an additional 424 shares in the last quarter. Signaturefd LLC grew its position in shares of Ionis Pharmaceuticals by 45.6% in the first quarter. Signaturefd LLC now owns 1,382 shares of the company's stock valued at $42,000 after purchasing an additional 433 shares in the last quarter. Treasurer of the State of North Carolina grew its position in shares of Ionis Pharmaceuticals by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 68,803 shares of the company's stock valued at $2,405,000 after purchasing an additional 440 shares in the last quarter. Finally, Fifth Third Bancorp grew its position in shares of Ionis Pharmaceuticals by 4.8% in the first quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock valued at $301,000 after purchasing an additional 458 shares in the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.